Table 3 Treatment outcomes of propensity score-matched ICU patients with nosocomial pneumonia treated with and without add-on tigecycline in combination regimen
| Â | Original cohort | PS-matched cohort | ||||
|---|---|---|---|---|---|---|
With add-on tigecycline | Without add-on tigecycline | P value | With add-on tigecycline | Without add-on tigecycline | P value | |
Case number | 148 | 247 | Â | 102 | 102 | Â |
Clinical failure | ||||||
 Day 7 | 64 (43.2%) | 103 (41.7%) | 0.764 | 38 (37.3%) | 53 (52.0%) | 0.035 |
 Day 14 | 58 (39.2%) | 118 (47.8%) | 0.097 | 40 (39.2%) | 59 (57.8%) | 0.008 |
 Day 28 | 67 (45.3%) | 121 (49.0%) | 0.474 | 47 (46.1%) | 64 (62.7%) | 0.017 |
All-cause mortality | ||||||
 Day 28 | 41 (27.7%) | 89 (36.0%) | 0.088 | 29 (28.4%) | 54 (52.9%) | < 0.001 |
 Hospital mortality | 74 (50.0%) | 120 (48.6%) | 0.785 | 54 (52.9%) | 70 (68.6%) | 0.022 |
28-day ventilator weaninga | 66/144 (45.8%) | 105/223 (47.1%) | 0.814 | 41/100 (41.0%) | 29/91 (31.9%) | 0.191 |
Newly onset dialysisb | 11 (7.4%) | 23 (9.3%) | 0.519 | 9 (8.8%) | 13 (12.7%) | 0.367 |
ICU stays (median, IQR) (days) | 27 (17–46) | 23 (15–40) | 0.386 | 27.5 (18–44) | 24.5 (16–42) | 0.931 |
Hospital stays (median, IQR) (days) | 51 (35–79) | 46 (30–68) | 0.268 | 51 (37–80) | 41.5 (26–68) | 0.827 |